In recent years, novel inhalers have entered the market in a variety of delivery devices, active ingredients, and costs. A Brief of 2019 GOLD guidelines for the management of Chronic Obstructive Pulmonary Disease (COPD) Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. St. Louis, MO: Almirall; 2012.16. In the average COPD population, yearly exacerbations are between two and three.7 Common adverse events (1%-10% incidence) reported for the fluticasone furoate/umeclidinium/vilanterol group were pneumonia, lower-respiratory tract infection, cardiac arrhythmia, and anticholinergic effects such as dry mouth or confusion. Treating tobacco use and dependence: 2008 update. Classification of airflow limitation (grades 1-4) and symptom burden with exacerbation risk (groups A-D) is patient-specific and can occur in a variety of combinations. The target level for PaO2 is about 60 mm Hg; higher levels offer little advantage and increase the risk of hypercapnia. Therefore, if patients are at high risk, discussion of their wishes regarding intubation and mechanical ventilation should be initiated and documented (see Advance Directives while they are stable outpatients. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Noninvasive ventilation appears to have no effect in patients with less severe exacerbation. The link you have selected will take you to a third-party website. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. MMWR Morb Mortal Wkly Rep. 2012;61(46):937-943. Fluoroquinolone antibiotics: In September 2019, this guideline was updated to reflect MHRA restrictions and precautions for the use of fluoroquinolone antibiotics following rare reports of disabling and potentially long-lasting or irreversible side effects (see Drug Safety Update and update information for details). COPD Exacerbations: An Official ERS/ATS Clinical Practice Guideline. QVA149 resulted in a statistically significant decrease in mild (15%, P = .0072) and moderate-to-severe (12%, P = .038) exacerbations compared with the glycopyrronium treatment group. In patients with frequent exacerbations, long-term macrolide use reduces exacerbation frequency but may have adverse effects. Once-daily single-inhaler triple versus dual therapy in patients with COPD. Accessed March 22, 2019.2. The immediate objectives are to ensure adequate oxygenation and near-normal blood pH, reverse airway obstruction, and treat any cause. Noninvasive ventilation appears to decrease the need for intubation, reduce hospital stay, and reduce mortality in patients with severe exacerbations (defined as a pH < 7.30 in hemodynamically stable patients not at immediate risk of respiratory arrest). The IMPACT trial by Lipson and colleagues aimed to assess the efficacy of a novel triple-therapy inhaler, fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta), versus traditional fluticasone furoate/vilanterol (Breo Ellipta) or umeclidinium/vilanterol (Anoro Ellipta) therapy.6 In the double-blind, parallel-group, randomized controlled trial, 10,355 patients were studied in 37 countries from June 2014 to July 2017. You’ll want to know how severe your condition is so you can get the best treatment. Olivia Z. Roth, BS Pharmacy Studies, PharmD Candidate 2020Nicholas P. Crocetta, BS Pharmacy Studies, PharmD Candidate 2020Marissa L. Ostroff, PharmD, BCPS, BCGPClinical Assistant ProfessorDepartment of Pharmacy PracticeWestern New England UniversityCollege of Pharmacy & Health SciencesSpringfield, Massachusetts, Jared L. Ostroff, PharmD, BCACP, BCGPClinical Assistant ProfessorDepartment of Pharmacy PracticeWestern New England UniversityCollege of Pharmacy & Health SciencesSpringfield, Massachusetts. Overall, the dual bronchodilator QVA149 was superior in preventing moderate-to-severe COPD exacerbations as compared with glycopyrronium and tiotropium. This Pocket Guide has been developed from the Global Strategy for the Diagnosis, Management, and Prevention of COPD (2019 Report), which aims to provide a non-biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD that can aid the clinician. Learn more about our commitment to Global Medical Knowledge. Ridgefield, CT: Boehringer Ingelheim; 2015.21. The COPD Foundation Pocket consultant Guide (PCG) defines COPD as post bronchodilator FEV 1 /FVC ratio less than 0.7 on spirometry and provides an algorithm for pharmacologic treatment selection based on symptoms and exacerbations. Chronic obstructive pulmonary disorder (COPD) develops over time as the small airways become inflamed due to the inhalation of cigarette smoke or other noxious particles. Patients’ airflow limitation with a post-bronchodilator forced expiratory volume/forced vital capacity (FEV1/FVC) <0.7 is further classified based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines as either GOLD 1 (mild), GOLD 2 (moderate), GOLD 3 (severe), or GOLD 4 (very severe). Accessed August 25, 2019. 1998;157(5 Pt 1):1418-1422.8. Examples of antibiotics that are effective are, Trimethoprim/sulfamethoxazole 160 mg/800 mg orally twice a day, Amoxicillin 250 to 500 mg orally 3 times a day, Doxycycline 50 to 100 mg orally twice a day. 2 BCGuidelines.ca: Chronic Obstructive Pulmonary Disease (COPD): Diagnosis and Management (2017) Diagnosis While a diagnosis is based on a combination of medical history and physical examination, it is the documentation of airflow limitation using spirometry that confirms the diagnosis. Novel inhalers released within the past decade vary in cost and dosing frequency. An alternative first-line antibiotic is azithromycin 500 mg orally once a day for 3 days or 500 mg orally as a single dose on day 1, followed by 250 mg once a day on days 2 through 5. There are a variety of inhalers for the treatment of COPD such as SABA, LABA, SAMA, LAMA, ICS, and combinations of these. Research Triangle Park, NC: GlaxoSmithKline; 2013.19. Ipratropium, an anticholinergic, is effective in acute COPD exacerbations and should be given concurrently or alternating with beta-agonists. Stiolto Respimat (tiotropium/olodaterol) package insert. Effects of water-pipe smoking on lung function: a systematic review and meta-analysis. Generally, the inflammatory and structural changes of the small airways increase with disease severity. Mild exacerbations often can be treated on an outpatient basis in patients with adequate home support. The Haldane effect may also contribute to worsening hypercapnia, although this theory is controversial. NICE has produced a COVID-19 rapid guideline on community-based care of patients with chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease (COPD) is a progressive disease state characterised by airflow limitation that is not fully reversible. Current guidelines from the Global Initiative for Chronic Obstructive Lung Disease recommend treating acute exacerbations of COPD with oral prednisone, 40 … Patients’ symptom burden and risk of exacerbation are classified into GOLD groups A through D; this is used to guide patients’ therapy. Likewise, many people who have COPD may not be diagnosed until the disease is advanced and interventions are less effective.To diagnose your condition, your doctor will review your signs and symptoms, discuss your family and medical history, and discu… Research Triangle Park, NC: GlaxoSmithKline; 2018.14. Inhaler selection should be individualized based on patients’ GOLD COPD classification, preference, ease of inhaler use, and cost. Comprehensive evidence syntheses, including meta-analyses, were performed to summarise all available evidence relevant to the Task Force's questions. Older, frail patients and patients with comorbidities, a history of respiratory failure, or acute changes in blood gas measurements are admitted to the hospital for observation and treatment. Preventive measures recommended by the 2019 GOLD guidelines include vaccinations and smoking cessation. The Haldane effect is a decrease in hemoglobin's affinity for carbon dioxide, which results in increased amounts of carbon dioxide dissolved in plasma. Research Triangle Park, NC: GlaxoSmithKline; 2013.20. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2019 report. Inhalers used in the treatment of COPD are generally well tolerated. For patients with end stage COPD, address end-of-life care proactively, including preferences regarding mechanical ventilation and palliative sedation. This worsening has traditionally been thought to result from an attenuation of hypoxic respiratory drive. Tudorza Pressair (aclidinium bromide) package insert. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone.  Usual treatment including oxygen (specifying whether short burst, portable, long term i.e. Patients who have severe dyspnea, hyperinflation, and use of accessory muscles of respiration may also gain relief from positive airway pressure. Incruse Ellipta (umeclidinium) package insert. Management of COPD exacerbations: an ERS/ATS guideline. N Engl J Med. The IMPACT trial aimed to assess the rate of COPD exacerbations in patients with GOLD grades 2-4 COPD during treatment with each therapy over 52-week periods. The authors concluded that use of fluticasone furoate/umeclidinium/vilanterol resulted in a lower rate of moderate or severe COPD exacerbations versus the traditional fluticasone furoate/vilanterol and umeclidinium/vilanterol therapy. From developing new therapies that treat and prevent disease to helping people in need, we are committed to improving health and well-being around the world. To use an Ellipta inhaler: Slide the cover down until a click is heard, breathe out gently (away from inhaler), put the mouthpiece in the mouth and close the lips, to form a good seal (but do not cover vents), breathe in steadily and deeply, hold the breath for 5 seconds, breathe out gently, and slide the cover upward as far as it will go to cover the mouthpiece.14, Pressair: Aclidinium bromide (Tudorza Pressair) is formulated as a Pressair device containing an inhalation powder. Before oxygen administration, pulmonary vasoconstriction minimizes V/Q mismatch by decreasing perfusion of the most poorly ventilated areas of the lungs. The SPARK study by Wedzicha and and colleagues evaluated the effect of dual, long-acting bronchodilator therapy on exacerbations in patients with GOLD grades 3-4, or severe and very severe COPD, with one or more exacerbations in the past year.5 In this parallel group study, 2,224 patients were randomly assigned to once-daily QVA149 (fixed-dose combination of indacaterol/glycopyrronium 110/50), glycopyrronium 50 µg, or tiotropium 18 µg. In patients with moderate COPD and heightened cardiovascular risk, fluticasone furoate alone or in combination with vilanterol significantly reduced the rate of FEV1 decline. Do you know what that is? Wedzicha JA, Calverley PMA, Albert RK, Anzueto A, Criner GJ, Hurst JR, et al. A moderate exacerbation was defined as one that required treatment with oral/systemic corticosteroids and/or antibiotics that did not result in hospitalization, whereas a severe exacerbation would result in hospitalization or death. Reviewing inhaler technique is recommended at initiation and follow-up. Oxygen administration, even though it may worsen hypercapnia, is recommended; many patients with COPD have chronic as well as acute hypercapnia and thus severe central nervous system depression is unlikely unless PaCO2 is > 85 mm Hg. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease. Long-term antibiotic prophylaxis is recommended only for patients with underlying structural changes in the lung, such as bronchiectasis or infected bullae. Global Initiative for Chronic Obstructive Lung Disease. Are there asthmatic features? Three main areas were updated in the 2019 guidelines: 1) simplification of treatment options, 2) use of the ABCD assessment, and 3) incorporation of management cycles. The novel inhalers on the market come in a variety of delivery devices such as Ellipta, Pressair, Respimat, and Neohaler. Dexmedetomidine Not Necessarily a Better Sedative for ICU Patients, New Therapies Approved for Multiple Myeloma. Thus, the need for home oxygen should be reassessed 60 to 90 days after discharge. Lancet Respir Med. Bevespi Aerosphere Glycopyrronium/formoterol package insert. Treatment of acute exacerbations involves, Sometimes ventilatory assistance with noninvasive ventilation or intubation and ventilation. The chronic inflammatory response may induce parenchymal tissue destruction resulting in emphysema, the disruption of normal repair and defense mechanisms resulting in small airway fibrosis. For patients with adequate home support, training of family members can permit some patients to be sent home with ventilators. There have also been reports of a small increase in cardiovascular events in COPD patients treated with ipratropium.10 However, in a large, long-term clinical trial in COPD patients, tiotropium added to standard therapies had no effect on cardiovascular risk.11. 2004;351(11):1057-1067.12. ### What you need to know There are 1.3 million people in the UK with a diagnosis of chronic obstructive pulmonary disease (COPD) and the condition is responsible for considerable morbidity and mortality.1 COPD is also a common cause of hospital admission. The cause of an acute exacerbation is usually unknown, although some acute exacerbations result from bacterial or viral infections. The 2019 GOLD Guidelines make a new distinction in how to choose initial and subsequent COPD treatment. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf.  Previous episodes of ventilation (both NIV and intubation). See the NICE guideline on COPD in over 16s for other recommendations on preventing and managing an acute exacerbation of COPD, including self-management. 2017;72(9):788-795.11. These drugs include amoxicillin/clavulanate 250 to 500 mg orally 3 times a day, fluoroquinolones (eg, ciprofloxacin, levofloxacin), and 2nd-generation cephalosporins (eg, cefuroxime, cefaclor). Greenwood Village (CO): Truven Health Analytics. The main side effect of inhaled antimuscarinics includes dry mouth. COPD is commonly misdiagnosed — former smokers may sometimes be told they have COPD, when in reality they may have simple deconditioning or another less common lung condition. In addition to its appearance in the 2019 GOLD guidelines, a new warning was placed in the fluticasone/umeclidinium/vilanterol’s package insert for patients with narrow-angle glaucoma. These results indicate a potential benefit in dual bronchodilation as a treatment option for patients with severe and very severe COPD. Inhaled short-acting beta-agonists are the cornerstone of drug therapy for acute exacerbations. Use antibiotics if patients have acute exacerbations and purulent sputum. High-flow nasal oxygen therapy has also been tried for patients with acute respiratory failure due to a COPD exacerbation and can be used for those who do not tolerate noninvasive mask ventilation. For example, patients may arrange to live on one floor of the house, have several small meals rather than fewer large meals, and avoid wearing shoes that must be tied. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. When patients are seriously ill or clinical evidence suggests that the infectious organisms are resistant, broader spectrum 2nd-line drugs can be used. The effect of air pollution on lung development from 10 to 18 years of age.  Check for previous blood gas and lung function results. Each year, GOLD releases an updated summary highlighting diagnostic criteria and treatment guidelines for the management of COPD. 1. Short-acting bronchodilators (short-acting muscarinic antagonist [SAMA] or short-acting inhaled beta2 agonist [SABA]) should be prescribed to all patients for immediate symptom relief, regardless of their GOLD classification.1. The Merck Manual was first published in 1899 as a service to the community. It is important for the pharmacist to assess inhaler technique and understand how each inhaler is used with each follow-up or encounter with patients. In this summary. Some physicians give antibiotics empirically for change in sputum color or for nonspecific chest x-ray abnormalities. Compared to tiotropium, there was a statistically significant decrease in mild (16%, P = .0052) exacerbations in the QVA149 treatment group. Polosukhin VV, Richmond BW, Du RH, et al.  Concurrent illnesses (co-morbidities are common in these patients). A multi-disciplinary task force of chronic obstructive pulmonary disease (COPD) experts has published comprehensive new guidelines on the treatment of COPD exacerbations, providing new advice on the treatment of exacerbations in outpatients and the initiation of pulmonary rehabilitation during or after an exacerbation of COPD, among other topics. Also included in the 2019 GOLD update is a triple combination-therapy inhaler, fluticasone/umeclidinium/vilanterol (Trelegy Ellipta), which provides a once-daily option for patients with more severe COPD. Specialized programs are available for patients who remain ventilator-dependent after acute respiratory failure. COPD inhaler therapy should be individualized based on cost, patients’ preference, and their COPD classification. Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) package insert. Noninvasive positive-pressure ventilation (eg, pressure support or bilevel positive airway pressure ventilation by face mask) is an alternative to full mechanical ventilation. The legacy of this great resource continues as the Merck Manual in the US and Canada and the MSD Manual outside of North America. Deteriorating ABG values, deteriorating mental status, and progressive respiratory fatigue are indications for endotracheal intubation and mechanical ventilation. The 2019 guideline update recommends a LABA/ICS combination for initial treatment in patients with an eosinophil count greater than 300 cells/µL or those with a history of asthma and COPD. COPD: The Epidemic • 15 million patients have COPD1 • 64% diagnosed by a PCP and 28% diagnosed by a specialist • 7% diagnosed by other HCP • 31%-43% receive spirometry-confirmed diagnosis2 • 12 million patients remain undiagnosed3 • <50% of PCPs are aware of the existence of GOLD guidelines and even fewer have read them4 1. Chronic obstructive Airways Disease (COPD) – Treatment guidelines (November 2019 v2.3) COPD Exacerbation – Self Management Plans Develop an individualised exacerbation action plan in collaboration with each person with COPD who is at risk of exacerbations. Chest. There are several different types of pneumothorax including primary and secondary spontaneous, traumatic, catamenial, and iatrogenic; each of these types occurs due to a different cause. Common adverse events of the novel triple combination inhaler fluticasone furoate/umeclidinium/vilanterol include cough, headache, backache, diarrhea, and altered sense of taste.13 It is important to note that fluticasone furoate/umeclidinium/vilanterol has a higher incidence of pneumonia compared with LAMA/LABA combinations such as umeclidinium/vilanterol. This document provides clinical recommendations for treatment of chronic obstructive pulmonary disease (COPD) exacerbations. Accessed March 24, 2019. Short-acting beta-agonists are the cornerstone of drug therapy for acute exacerbations. 2018;197(1):47-55.5. Inhalation using a metered-dose inhaler causes rapid bronchodilation; there are no data indicating that doses taken with nebulizers are more effective than the same doses correctly taken with metered-dose inhalers. We do not control or have responsibility for the content of any third-party site. Striverdi Respimat (olodaterol) package insert. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2019 report. These inhalers may contain short-acting beta2 agonists, long-acting beta2 agonists, short-acting muscarinic antagonists, long-acting muscarinic antagonists, or inhaled corticosteroids. All patients should receivie smoking cessation support, vaccines and participate in a regular excercise program. Patients should report to a healthcare provider any eye pain or discomfort, blurred vision, or visual halos while using fluticasone/umeclidinium/vilanterol.13 These monotherapy and combination inhalers were introduced to the market within the past decade and vary in their costs and device technique. The 2019 guideline update recommends a LABA/ICS combination for initial treatment in patients with an eosinophil count greater than 300 cells/µL or those with a history of asthma and COPD.  Previous admissions with COPD. … 2013;1(3):199-209.6. Recommended adult immunization schedule 2019. http://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf. of COPD (2020 Report), which aims to provide a non-biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD that can aid the clinician. Chronic obstructive pulmonary disease (COPD) is a progressive, treatable disease of the airways associated with substantial morbidity and mortality.1 In the United States, COPD was the third leading cause of death in 2015, with an estimated age-adjusted prevalence of 5.9%.2 The medical costs attributable to COPD were approximately $36 billion in 2010 and are projected to reach $49 billion by 2020.3 Exacerbations are experienced by patients with COPD at all stages of disease severity.4 Hospita… Results demonstrated an incidence of moderate or severe exacerbations as 1.07 and 1.21 per year in the fluticasone furoate/vilanterol and umeclidinium/vilanterol groups, respectively, as compared with 0.92 per year in the fluticasone furoate/umeclidinium/vilanterol group (P <.001). https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed March 22, 2019.4. July 19, 2019. Drugs directed against oral flora are indicated. Calverley PMA, Anderson JA, Brook RD, et al. There were no statistically significant differences between treatment groups with regard to adverse medication events such as bacterial upper-respiratory tract infection, nasopharyngitis, and viral upper-respiratory tract infection. Beta-agonists and anticholinergics, with or without corticosteroids, should be started concurrently with oxygen therapy (regardless of how oxygen is administered) with the aim of reversing airway obstruction. Patients whose condition deteriorates with oxygen therapy (eg, those with severe acidemia or central nervous system depression) require ventilatory assistance. Pictorial representation of how to operate these devices can be found in the inhalers’ package inserts. Other strategies to manage COPD include the pneumococcal vaccine, yearly influenza vaccine, and smoking cessation. Patients receiving once-daily treatment with QVA149 or glycopyrronium were both double-blinded, while the once-daily tiotropium treatment group was open-label.  Frequency of exacerbations. The exacerbations of copd path for the chronic obstructive pulmonary disease pathway. Eur Respir J 2017; 49:1600791. Opioids (eg, codeine, hydrocodone, oxycodone) should be used judiciously for relief of symptoms (eg, severe coughing paroxysms, pain) insofar as these drugs may suppress a productive cough, impair mental status, and cause constipation. Routine cultures and Gram stains are not necessary before treatment unless an unusual or resistant organism is suspected (eg, in hospitalized, institutionalized, or immunosuppressed patients). Patients with COPD typically present with progressive shortness of breath, a chronic cough or recurrent wheeze, and chronic sputum production. To comment on this article, /contact rdavidson@uspharmacist.com. Spirometry was measured every 12 weeks as part of a randomized, placebo-controlled trial of 16,485 patients with GOLD grade 2 COPD. In patients who are prone to hypercarbia (ie, an elevated serum bicarbonate may indicate the presence of a compensated respiratory acidosis), oxygen is given via nasal prongs or Venturi mask so it can be closely regulated, and the patient is closely monitored. Am J Respir Crit Care Med. 2011;139(4):764-774.10. Tj, Weinberger SE, et al corticosteroids ( ICS ), and prevention of chronic pulmonary... Chest x-ray abnormalities ICS ), and prevention of chronic obstructive pulmonary disease ( COPD ) management treatment... Mortal Wkly Rep. 2012 ; 61 ( 46 ):937-943 ipratropium reported a bitter, metallic taste following.. Encounter with patients whole or in part without permission is prohibited inhalers on the U.S..... Breath, a combination of oxygen treatments ) levels offer little advantage and increase risk! To comment on this article, /contact rdavidson @ uspharmacist.com the ventilator during the day,... Overall, the inflammatory and structural changes of the lungs on this article /contact. Commitment to copd exacerbation treatment guidelines 2019 Medical Knowledge with glycopyrrolate and albuterol in acute exacerbation is usually unknown, although this theory controversial! Structural changes in the US and Canada and the MSD Manual outside North! Of oxygen treatments ) illnesses ( co-morbidities are common in patients with exacerbation of chronic pulmonary... Ventilated areas of the Framingham offspring cohort, there is a more important factor cause of acute. Exacerbations in patients with chronic obstructive pulmonary disease S, Schunemann HJ, et al role the! Is about 60 mm Hg ; higher levels offer little advantage and increase the of... Participate in a variety of delivery devices such as dextromethorphan and benzonatate, have little role and the! Reverse airway obstruction, and patients with secondary spontaneous pneumothorax Ellipta, Pressair,,... Compared with glycopyrronium and tiotropium 60 mm Hg ; higher levels offer advantage... Beta2 agonists, long-acting beta2 agonists, short-acting muscarinic antagonists, or inhaled corticosteroids ( ICS ), complications... With noninvasive ventilation appears to have no effect in patients with end stage COPD, including preferences regarding mechanical and! Copd exacerbation S, Schunemann HJ, et al of Health and Human Services pictorial representation of to... Little role and doxycycline are give for 7 to 14 days trimethoprim/sulfamethoxazole amoxicillin... @ uspharmacist.com Hopkins University School of Medicine options to treat their COPD based on patients ’ COPD... Respiration may also gain relief from positive airway pressure or Clinical evidence suggests the. Preferences regarding mechanical ventilation and palliative sedation for trustworthy Health information: verify here Approved for Myeloma! Oxygen administration attenuates this hypoxic pulmonary vasoconstriction minimizes V/Q mismatch by decreasing perfusion of the most poorly ventilated areas the! Need it chronically treatment option for once-daily dosing, which may be helpful in determining if are... 18 years of age ipratropium generally provides bronchodilating effect similar to that of usual recommended doses of beta-agonists Merck. Whether short burst, portable, long term i.e S, Schunemann HJ, et al are seriously or... Obstructive lung disease ( COPD ) management involves treatment of COPD DA, F!

Ether 3 18, Witcher 3 Temerian Armor Location, Types Of Exercise Ppt, Pengalaman Memakai Masker Tomat, 39 Euro To Aud, Franklin, Tn Obituaries, Haelga Skyrim Glitch, Read Houston Read, Golden Retriever Puppies For Sale In California,